Safeguarding the administration of high-dose chemotherapy: A national practice survey by the American Society for Blood and Marrow Transplantation

Chien Shing Chen, Kristy Seidel, James Olen Armitage, Joseph W. Fay, Frederick R. Appelbaum, Mary M. Horowitz, Elizabeth J. Shpall, Paul L. Weiden, Karen S. Antman, Richard E. Champlin, John H. Kersey, Keith M. Sullivan

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Overdoses of high-dose chemotherapy before hematopoietic cell transplantation are serious adverse events, but their frequency and etiology are unknown. The American Society for Blood and Marrow Transplantation (ASBMT) conducted an anonymous national survey to identify errors in safety practices during the administration of high-dose chemotherapy. The questionnaire was returned from 115 (68%) of 170 hematopoietic transplant centers in the United States. Ninety-four of the programs were university or affiliated centers, 19 were community hospitals, and 41 were founded since 1990. A total of 7650 transplants were reported for 1994: 22% of the programs performed 1-20 transplants, 60% performed 21-100 transplants, and 18% performed more than 100 transplants. Fifteen of the 115 responding centers reported a total of 18 patients inadvertently given overdoses of cisplatin (n=3), carboplatin (n=2), busulfan (n=2), cytosine arabinoside (n=2), cyclophosphamide (n=2), interleukin-2 (n=2), or other agents (n=5) between 1989 and 1994. Cumulative drug doses given as a daily dose (six cases) and nursing infusion errors (six cases) were the most common errors. The estimated chemotherapy overdose error rate was 0.06%, or 6 cases/10,000 transplants, with 95% confidence limits of 0.03-0.11%. The overdose rate among more experienced centers in operation before 1990 was lower than that among newer centers (p < 0.01). Large centers (>100 transplants performed in 1994) experienced errors at rates lower than those in medium-sized centers (21-100 transplants, p = 0.03). Although the number of events was small in this self-reporting survey, overdoses were noted in 13% of the responding centers, especially among more recently established units. Safety practices need to emphasize multidisciplinary checkpoints at the physician, pharmacist, nursing, and institutional levels. Based on these survey results, ASBMT recommendations for further safeguards for high-dose chemotherapy administration are proposed.

Original languageEnglish (US)
Pages (from-to)331-340
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume3
Issue number6
StatePublished - Dec 1 1997

Fingerprint

Transplantation
Bone Marrow
Transplants
Drug Therapy
Nursing
Safety
Busulfan
Surveys and Questionnaires
Carboplatin
Cytarabine
Cell Transplantation
Community Hospital
Pharmacists
Cyclophosphamide
Cisplatin
Interleukin-2
Physicians
Pharmaceutical Preparations

Keywords

  • Bone marrow transplantation
  • High-dose chemotherapy
  • Medication errors
  • Physician orders

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Safeguarding the administration of high-dose chemotherapy : A national practice survey by the American Society for Blood and Marrow Transplantation. / Chen, Chien Shing; Seidel, Kristy; Armitage, James Olen; Fay, Joseph W.; Appelbaum, Frederick R.; Horowitz, Mary M.; Shpall, Elizabeth J.; Weiden, Paul L.; Antman, Karen S.; Champlin, Richard E.; Kersey, John H.; Sullivan, Keith M.

In: Biology of Blood and Marrow Transplantation, Vol. 3, No. 6, 01.12.1997, p. 331-340.

Research output: Contribution to journalReview article

Chen, CS, Seidel, K, Armitage, JO, Fay, JW, Appelbaum, FR, Horowitz, MM, Shpall, EJ, Weiden, PL, Antman, KS, Champlin, RE, Kersey, JH & Sullivan, KM 1997, 'Safeguarding the administration of high-dose chemotherapy: A national practice survey by the American Society for Blood and Marrow Transplantation', Biology of Blood and Marrow Transplantation, vol. 3, no. 6, pp. 331-340.
Chen, Chien Shing ; Seidel, Kristy ; Armitage, James Olen ; Fay, Joseph W. ; Appelbaum, Frederick R. ; Horowitz, Mary M. ; Shpall, Elizabeth J. ; Weiden, Paul L. ; Antman, Karen S. ; Champlin, Richard E. ; Kersey, John H. ; Sullivan, Keith M. / Safeguarding the administration of high-dose chemotherapy : A national practice survey by the American Society for Blood and Marrow Transplantation. In: Biology of Blood and Marrow Transplantation. 1997 ; Vol. 3, No. 6. pp. 331-340.
@article{e8eafa6ac343489284ef2f6a03d6795b,
title = "Safeguarding the administration of high-dose chemotherapy: A national practice survey by the American Society for Blood and Marrow Transplantation",
abstract = "Overdoses of high-dose chemotherapy before hematopoietic cell transplantation are serious adverse events, but their frequency and etiology are unknown. The American Society for Blood and Marrow Transplantation (ASBMT) conducted an anonymous national survey to identify errors in safety practices during the administration of high-dose chemotherapy. The questionnaire was returned from 115 (68{\%}) of 170 hematopoietic transplant centers in the United States. Ninety-four of the programs were university or affiliated centers, 19 were community hospitals, and 41 were founded since 1990. A total of 7650 transplants were reported for 1994: 22{\%} of the programs performed 1-20 transplants, 60{\%} performed 21-100 transplants, and 18{\%} performed more than 100 transplants. Fifteen of the 115 responding centers reported a total of 18 patients inadvertently given overdoses of cisplatin (n=3), carboplatin (n=2), busulfan (n=2), cytosine arabinoside (n=2), cyclophosphamide (n=2), interleukin-2 (n=2), or other agents (n=5) between 1989 and 1994. Cumulative drug doses given as a daily dose (six cases) and nursing infusion errors (six cases) were the most common errors. The estimated chemotherapy overdose error rate was 0.06{\%}, or 6 cases/10,000 transplants, with 95{\%} confidence limits of 0.03-0.11{\%}. The overdose rate among more experienced centers in operation before 1990 was lower than that among newer centers (p < 0.01). Large centers (>100 transplants performed in 1994) experienced errors at rates lower than those in medium-sized centers (21-100 transplants, p = 0.03). Although the number of events was small in this self-reporting survey, overdoses were noted in 13{\%} of the responding centers, especially among more recently established units. Safety practices need to emphasize multidisciplinary checkpoints at the physician, pharmacist, nursing, and institutional levels. Based on these survey results, ASBMT recommendations for further safeguards for high-dose chemotherapy administration are proposed.",
keywords = "Bone marrow transplantation, High-dose chemotherapy, Medication errors, Physician orders",
author = "Chen, {Chien Shing} and Kristy Seidel and Armitage, {James Olen} and Fay, {Joseph W.} and Appelbaum, {Frederick R.} and Horowitz, {Mary M.} and Shpall, {Elizabeth J.} and Weiden, {Paul L.} and Antman, {Karen S.} and Champlin, {Richard E.} and Kersey, {John H.} and Sullivan, {Keith M.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "331--340",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Safeguarding the administration of high-dose chemotherapy

T2 - A national practice survey by the American Society for Blood and Marrow Transplantation

AU - Chen, Chien Shing

AU - Seidel, Kristy

AU - Armitage, James Olen

AU - Fay, Joseph W.

AU - Appelbaum, Frederick R.

AU - Horowitz, Mary M.

AU - Shpall, Elizabeth J.

AU - Weiden, Paul L.

AU - Antman, Karen S.

AU - Champlin, Richard E.

AU - Kersey, John H.

AU - Sullivan, Keith M.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Overdoses of high-dose chemotherapy before hematopoietic cell transplantation are serious adverse events, but their frequency and etiology are unknown. The American Society for Blood and Marrow Transplantation (ASBMT) conducted an anonymous national survey to identify errors in safety practices during the administration of high-dose chemotherapy. The questionnaire was returned from 115 (68%) of 170 hematopoietic transplant centers in the United States. Ninety-four of the programs were university or affiliated centers, 19 were community hospitals, and 41 were founded since 1990. A total of 7650 transplants were reported for 1994: 22% of the programs performed 1-20 transplants, 60% performed 21-100 transplants, and 18% performed more than 100 transplants. Fifteen of the 115 responding centers reported a total of 18 patients inadvertently given overdoses of cisplatin (n=3), carboplatin (n=2), busulfan (n=2), cytosine arabinoside (n=2), cyclophosphamide (n=2), interleukin-2 (n=2), or other agents (n=5) between 1989 and 1994. Cumulative drug doses given as a daily dose (six cases) and nursing infusion errors (six cases) were the most common errors. The estimated chemotherapy overdose error rate was 0.06%, or 6 cases/10,000 transplants, with 95% confidence limits of 0.03-0.11%. The overdose rate among more experienced centers in operation before 1990 was lower than that among newer centers (p < 0.01). Large centers (>100 transplants performed in 1994) experienced errors at rates lower than those in medium-sized centers (21-100 transplants, p = 0.03). Although the number of events was small in this self-reporting survey, overdoses were noted in 13% of the responding centers, especially among more recently established units. Safety practices need to emphasize multidisciplinary checkpoints at the physician, pharmacist, nursing, and institutional levels. Based on these survey results, ASBMT recommendations for further safeguards for high-dose chemotherapy administration are proposed.

AB - Overdoses of high-dose chemotherapy before hematopoietic cell transplantation are serious adverse events, but their frequency and etiology are unknown. The American Society for Blood and Marrow Transplantation (ASBMT) conducted an anonymous national survey to identify errors in safety practices during the administration of high-dose chemotherapy. The questionnaire was returned from 115 (68%) of 170 hematopoietic transplant centers in the United States. Ninety-four of the programs were university or affiliated centers, 19 were community hospitals, and 41 were founded since 1990. A total of 7650 transplants were reported for 1994: 22% of the programs performed 1-20 transplants, 60% performed 21-100 transplants, and 18% performed more than 100 transplants. Fifteen of the 115 responding centers reported a total of 18 patients inadvertently given overdoses of cisplatin (n=3), carboplatin (n=2), busulfan (n=2), cytosine arabinoside (n=2), cyclophosphamide (n=2), interleukin-2 (n=2), or other agents (n=5) between 1989 and 1994. Cumulative drug doses given as a daily dose (six cases) and nursing infusion errors (six cases) were the most common errors. The estimated chemotherapy overdose error rate was 0.06%, or 6 cases/10,000 transplants, with 95% confidence limits of 0.03-0.11%. The overdose rate among more experienced centers in operation before 1990 was lower than that among newer centers (p < 0.01). Large centers (>100 transplants performed in 1994) experienced errors at rates lower than those in medium-sized centers (21-100 transplants, p = 0.03). Although the number of events was small in this self-reporting survey, overdoses were noted in 13% of the responding centers, especially among more recently established units. Safety practices need to emphasize multidisciplinary checkpoints at the physician, pharmacist, nursing, and institutional levels. Based on these survey results, ASBMT recommendations for further safeguards for high-dose chemotherapy administration are proposed.

KW - Bone marrow transplantation

KW - High-dose chemotherapy

KW - Medication errors

KW - Physician orders

UR - http://www.scopus.com/inward/record.url?scp=0031310563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031310563&partnerID=8YFLogxK

M3 - Review article

C2 - 9502301

AN - SCOPUS:0031310563

VL - 3

SP - 331

EP - 340

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -